» Authors » Walter Kisiel

Walter Kisiel

Explore the profile of Walter Kisiel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 41
Citations 564
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wojtukiewicz M, Hempel D, Kruszewska J, Zimnoch L, Kisiel W, Sierko E
J BUON . 2016 Feb; 20(6):1426-31. PMID: 26854437
Purpose: Erythropoiesis-stimulating agents (ESAs) are recommended for treating chemotherapy-induced anemia in breast cancer patients. Reduced survival rates in ESAs-treated patients have been reported, possibly due to thromboembolic complications, however the...
2.
Zhu S, Kisiel W, Lu Y, Petersen L, Ndungu J, Moore T, et al.
J Drug Deliv . 2015 Jan; 2014:865732. PMID: 25574399
Breast cancer aberrantly expresses tissue factor (TF) in cancer tissues and cancer vascular endothelial cells (VECs). TF plays a central role in cancer angiogenesis, growth, and metastasis and, as such,...
3.
Zhu S, Kisiel W, Lu Y, Petersen L, Ndungu J, Moore T, et al.
J Drug Target . 2014 Dec; 23(3):257-65. PMID: 25510254
We have developed a specific technique for imaging cancer in vivo using Cy5.5-labeled factor VIIa (fVIIa), clotting-deficient FFRck-fVIIa, paclitaxel-FFRck-fVIIa, and anti-tissue factor (TF) antibody. FVIIa is the natural ligand for...
4.
Sierko E, Wojtukiewicz M, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W
Ann Hematol . 2013 Oct; 93(5):779-84. PMID: 24158387
In gastric cancer, hemostatic system components contribute to cancer progression, as activation of factor X (FX) was observed. The protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) complex inhibits factor Xa...
5.
Sierko E, Wojtukiewicz M, Zimnoch L, Tokajuk P, Ostrowska-Cichocka K, Kisiel W
Thromb Res . 2012 Mar; 129(4):e112-8. PMID: 22424030
Introduction: Several hemostatic system components, including factor X (FX), contribute to cancer progression. The Protein Z (PZ)/protein Z-dependent protease inhibitor (ZPI) complex directly inhibits factor Xa proteolytic activity. The aim...
6.
Sierko E, Wojtukiewicz M, Zimnoch L, Ostrowska-Cichocka K, Tokajuk P, Ramlau R, et al.
Thromb Res . 2011 Oct; 129(4):e92-6. PMID: 21975032
Introduction: NSCLC progression is often associated with VTE. Activation of factor X is an important step in blood coagulation activation in cancer patients. PZ)/ZPI contribute to direct factor Xa inhibition,...
7.
Sierko E, Wojtukiewicz M, Zimnoch L, Thorpe P, Brekken R, Kisiel W
Anticancer Res . 2011 Apr; 31(3):843-7. PMID: 21498704
Background: Colon cancer (CC) is frequently complicated by thromboembolic episodes. Thrombin plays a role in angiogenesis and among others induces the synthesis of vascular endothelial growth factor (VEGF) and its...
8.
Sierko E, Wojtukiewicz M, Zimnoch L, Tokajuk P, Kisiel W
Int J Hematol . 2011 Apr; 93(5):681-683. PMID: 21479979
No abstract available.
9.
Gillibert-Duplantier J, Rullier A, Neaud V, Kisiel W, Rosenbaum J
World J Gastroenterol . 2010 Jan; 16(2):210-6. PMID: 20066740
Aim: To study the protein C activation system in human liver myofibroblasts, and the effects of activated protein C (APC) on these cells. Methods: Human liver myofibroblasts were obtained by...
10.
Sierko E, Wojtukiewicz M, Zimnoch L, Kisiel W
Thromb Haemost . 2010 Jan; 103(1):198-204. PMID: 20062932
Activation of blood coagulation, a phenomenon frequently observed in breast and colon cancer patients, contributes to tumour progression. The principal initiator of blood coagulation activation in cancer patients is tissue...